The Division of Gynecologic Oncology has one of the largest Clinical Trial Research Programs in Northern California and is on the forefront of translational research in gynecologic cancers. Through the collaborative work of our providers, research team and other UCSF staff, we offer a wide variety of clinical trials that provide women with gynecologic cancers access to cutting edge investigational therapies and treatment methods. Our practice serves as a regional research hub which attracts patients from across California seeking out clinical trials. Additionally, we are a voting member of the national Cooperative Group NRG Oncology, an interdisciplinary research organization dedicated to improving the survival and quality of life of cancer patients through research, where we help to shape Gynecologic Oncology care on a national and global level. We are excited to continue to grow our Clinical Research Program by adding additional staff and expanding our trial portfolio, with the goal of being able to provide any woman with gynecologic cancer interested in participating in a clinical trial access to potentially life-saving therapy.
The following trials are currently open to accrual:
GARNET A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors NCT02715284 PI: Lee-may Chen, MD
MK3475-775 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with Advanced Endometrial Cancer NCT03517449 PI: Edwin Alvarez, MD
Cooperative Group Trials
NRG-GY005 (Currently on hold) A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) NCT02502266 PI: Jocelyn Chapman, MD
NRG-GY009 (Currently on hold) A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND#134427) Versus Pegylated Liposomal Doxorubicin/ Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/ Bevacizumab in Platinum Resistant Ovarian Cancer NCT02839707 PI: Edwin Alvarez, MD
GOG-3015 A Phase III, Multi-center, Randomized Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly Diagnosed Stage III or State IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03038100 PI: Lee-may Chen, MD
GOG-3009 A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV NCT02853604 PI: Stefanie Ueda, MD
If you would like more information regarding our Gynecologic Oncology Trials at UCSF, please email our team at [email protected].
For the most recent list of clinical trials, please visit: https://clinicaltrials.ucsf.edu.